CYTOTECHNOLOGY, an esteemed journal published by Springer, stands as a vital resource in the fields of Bioengineering, Biomedical Engineering, and Biotechnology. With an impact factor reflective of its solid position within academia, this journal encompasses a broad scope dedicated to the advancement of cytotechnological research and applications from its inception in 1987 through to its latest volumes in 2024. Based in the Netherlands, it is committed to providing researchers, professionals, and students with high-quality, peer-reviewed articles that contribute to the understanding and innovations in cytotechnology. Although currently not open access, CYTOTECHNOLOGY has garnered a commendable reputation, holding Q3 rankings in multiple categories, indicating its relevance and influence within the scientific community. Researchers are encouraged to submit their cutting-edge findings to share insights that can spark further advancements in this dynamic field.

OncoTargets and Therapy is a prestigious, peer-reviewed journal dedicated to the rapid dissemination of research in the fields of oncology and pharmacology. Published by DOVE MEDICAL PRESS LTD in New Zealand since 2008, this journal has embraced the open access model, ensuring that critical cancer-related research is freely accessible to a global audience. With an impressive impact factor reflected by its Q2 ranking in both the Oncology and Pharmacology (medical) categories for 2023, as well as Scopus rankings placing it in the top 91st percentile in pharmacology and the 84th percentile in oncology, OncoTargets and Therapy stands out as a vital resource for researchers, clinicians, and students alike. The journal focuses on therapeutics, novel drug discoveries, and clinical trials, encouraging collaborative efforts to combat cancer effectively. By providing a platform for groundbreaking studies and comprehensive reviews, it plays a crucial role in advancing knowledge and practice in these critical areas of medical science.

SEMINARS IN CANCER BIOLOGY is a leading journal dedicated to the dissemination of groundbreaking research in the field of cancer biology. Published by Academic Press Ltd - Elsevier Science Ltd, this esteemed journal plays a pivotal role in the academic community, boasting a prestigious impact factor and ranking within the Q1 category in Cancer Research for 2023. With an exceptional Scopus rank of #11 out of 230 in the realms of Biochemistry, Genetics, and Molecular Biology, it holds a significance that underscores its influence in advancing the understanding of cancer mechanisms and therapies. Established in 1990, the journal fosters a comprehensive platform for sharing high-quality and innovative research, critical reviews, and expert opinions aimed at professionals and researchers in the field. While not an open-access journal, it provides valuable insights that enhance the collective knowledge essential for the fight against cancer. For researchers, clinicians, and students, SEMINARS IN CANCER BIOLOGY is a crucial resource, paving the way for new discoveries and innovations in cancer treatment and prevention.

Cancer Reports, published by WILEY, is an esteemed open-access journal dedicated to the field of oncology and cancer research. With a focus on disseminating impactful research findings since its transition to fully open access in 2021, Cancer Reports aims to facilitate knowledge sharing among researchers, clinicians, and healthcare professionals globally. The journal is positioned within the Q3 quartile for both Cancer Research and Oncology categories as of 2023, reflecting its commitment to quality and relevance in a competitive publishing landscape. With an ISSN of N/A and an E-ISSN of 2573-8348, the journal showcases studies across diverse aspects of cancer biology, treatment modalities, and patient care strategies. Located in the United Kingdom at 111 River St, Hoboken 07030-5774, NJ, Cancer Reports strives to contribute to the advancement of cancer research and improve health outcomes for patients worldwide, making it a pivotal platform for scholars and practitioners in the oncology community.

Cancer Drug Resistance is a premier journal published by OAE PUBLISHING INC, focusing on the critical field of oncology and pharmacology. Since its inception in 2018, the journal has been at the forefront of presenting innovative research aimed at understanding and overcoming drug resistance in cancer therapy. With an impressive impact factor reflected in its Q2 ranking in Cancer Research and a Q1 ranking in Pharmacology (medical) for 2023, Cancer Drug Resistance serves as a vital resource for researchers, clinicians, and students who are dedicated to advancing cancer treatment and improving patient outcomes. The journal's commitment to disseminating high-quality, peer-reviewed articles underscores its importance within the academic and medical communities. While it operates on an open-access model, facilitating widespread distribution and access to crucial research findings, the journal continuously strives to foster dialogue and collaboration among stakeholders in cancer research and pharmacology. Its mission is clear: to shine a light on the evolving challenges and breakthroughs in drug resistance, paving the way for enhanced therapeutic strategies and clinical solutions.

MOLECULAR AND CELLULAR BIOLOGY, published by TAYLOR & FRANCIS INC, stands as a preeminent platform for researchers, professionals, and students engaged in the dynamic field of molecular and cellular biology. Established in 1981 and ongoing into 2024, the journal features cutting-edge research that spans across vital sub-disciplines, garnering a strong impact in its contributions to the scientific community. With an impressive Q2 ranking in Cell Biology and Q1 ranking in Molecular Biology for 2023, it consistently publishes high-quality articles that reflect the latest advancements and discoveries within the field. The journal is particularly well-regarded for its rigorous peer-review process and commitment to scientific excellence, making it an invaluable resource for those seeking to deepen their understanding of molecular mechanisms and cellular processes. Although not open access, the journal offers diverse access options for researchers to reach the latest findings. By maintaining a strong focus on biochemistry, genetics, and molecular biology, MOLECULAR AND CELLULAR BIOLOGY remains essential reading for anyone looking to contribute to or stay informed about significant developments within this pivotal area of study.

Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.

DRUG RESISTANCE UPDATES is a premier academic journal published by Churchill Livingstone, focusing on the critical areas of drug resistance in various diseases including cancer, infectious diseases, and the pharmacological challenges associated with these conditions. With a robust impact factor and a prestigious Q1 ranking across multiple categories such as Cancer Research, Infectious Diseases, and Pharmacology, this journal is recognized for its significant contributions to the field. Since its inception in 1998 and continuing through to 2024, it has become an essential resource for researchers, clinicians, and policy-makers aiming to understand and combat the evolving challenges of drug resistance. Although it is not an open-access publication, it provides vital insights and research findings that are pivotal in influencing treatment strategies and advancing knowledge within the scientific community. For stellar insights backed by rigorous peer review, DRUG RESISTANCE UPDATES should be on the radar of every professional concerned with the intricacies of modern medicine and pharmacology.

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

Animal Cells and Systems, published by TAYLOR & FRANCIS LTD, is a prominent open-access journal that has been disseminating high-quality research since 2017. With an ISSN of 1976-8354 and an E-ISSN of 2151-2485, this journal is dedicated to advancing the understanding of animal cellular biology and the intricate systems that govern organismal functions. Recognized for its rigorous peer-review process, it holds an esteemed position in the academic community, boasting a Q1 ranking in Animal Science and Zoology and a Q2 ranking in Biochemistry, Genetics and Molecular Biology for 2023. The journal is indexed in Scopus, ranked #79/490 in Animal Science and Zoology and #85/221 in General Biochemistry, Genetics, and Molecular Biology, affirming its impact and relevance in these fields. With a commitment to providing researchers, professionals, and students with vital insights and cutting-edge research, Animal Cells and Systems is an essential resource for those looking to explore the complex landscapes of animal biology.